Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Postoperative Recurrent Vitreous Haemorrhage in Diabetic Retinopathy
NCT05248334Phase 1Unknown
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ranibizumab in Vitreous hemorrhage (VH) and diabetic retinopathy (DR) (2 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoints: Cleaning time of postoperative recurrent vitreous hemorrhage at 2 months and Visual acuity at 6 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
Vitreous hemorrhage (VH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05248334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248334.